Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Expected to Announce Quarterly Sales of $32.14 Million

Analysts expect Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to report sales of $32.14 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Catalyst Pharmaceuticals’ earnings, with estimates ranging from $30.95 million to $34.00 million. Catalyst Pharmaceuticals reported sales of $29.14 million in the same quarter last year, which indicates a positive year over year growth rate of 10.3%. The firm is scheduled to announce its next quarterly earnings report on Monday, May 10th.

According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full year sales of $134.24 million for the current fiscal year, with estimates ranging from $125.72 million to $138.10 million. For the next financial year, analysts anticipate that the business will post sales of $157.50 million, with estimates ranging from $132.48 million to $174.40 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Tuesday, March 16th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. The firm had revenue of $31.02 million for the quarter, compared to analysts’ expectations of $30.06 million. Catalyst Pharmaceuticals had a return on equity of 35.04% and a net margin of 60.48%.

A number of analysts recently issued reports on the company. Roth Capital boosted their price objective on Catalyst Pharmaceuticals from $6.50 to $7.00 and gave the company a “buy” rating in a research note on Wednesday, March 24th. TheStreet raised Catalyst Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Thursday, February 18th. Four equities research analysts have rated the stock with a buy rating, Catalyst Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $7.63.

Catalyst Pharmaceuticals stock opened at $4.39 on Wednesday. Catalyst Pharmaceuticals has a 12 month low of $2.88 and a 12 month high of $5.19. The company has a market capitalization of $455.79 million, a PE ratio of 6.55 and a beta of 1.53. The stock has a 50-day moving average price of $4.21 and a two-hundred day moving average price of $3.72.

A number of large investors have recently bought and sold shares of CPRX. HealthInvest Partners AB bought a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at about $5,845,000. Royce & Associates LP grew its position in Catalyst Pharmaceuticals by 34.7% in the fourth quarter. Royce & Associates LP now owns 2,405,129 shares of the biopharmaceutical company’s stock worth $8,033,000 after acquiring an additional 620,239 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of Catalyst Pharmaceuticals by 139.0% during the fourth quarter. Nuveen Asset Management LLC now owns 916,829 shares of the biopharmaceutical company’s stock valued at $3,063,000 after buying an additional 533,282 shares during the period. Globeflex Capital L P purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $1,257,000. Finally, BlackRock Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 3.7% in the fourth quarter. BlackRock Inc. now owns 7,744,197 shares of the biopharmaceutical company’s stock valued at $25,866,000 after purchasing an additional 274,900 shares during the period. 64.86% of the stock is currently owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome.

See Also: Quiet Period Expirations Explained

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.